How One Chemical Manufacturer Saved $516K on Pharmacy Spend
Specialty medications are often the costliest line item on an employer’s pharmacy benefits bill. For the average self-funded plan, 2% of claims are for specialty medications, yet they account for 50+% of plan spend. For self-funded employers, managing these costs without compromising patient care is a delicate balancing act. A single high-cost claim can skew an entire budget, leaving benefits managers scrambling for answers.
This was the exact scenario facing a mid-sized chemical manufacturer. With pharmacy costs rising and one specific medication draining their resources, they needed a solution that went beyond standard cost-cutting measures. By partnering with RxBenefits, they uncovered a significant opportunity to optimize a cancer treatment plan, resulting in massive savings and a safer dosing regimen for the member.
Here is how one clinical intervention transformed their pharmacy plan management.
The Challenge: A Single Drug Dominating the Budget
Managing pharmacy benefits for more than 2,400 plan members is no small task. For this Midwest trust, the challenges were mounting on two fronts: financial sustainability and member experience.
Pharmacy costs were climbing, threatening the long-term viability of the plan. But the cost wasn’t the only issue. Members were facing hurdles every time they tried to fill their prescriptions. Whether navigating the prior authorization (PA) system or simply trying to get a straight answer about coverage, the experience was rife with friction.
For first responders, stress is part of the job description. Their health benefits should alleviate that stress, not add to it. The trust needed a partner who understood the unique pressures of their profession and could offer more than just a transaction. They needed an advocate.
The RxBenefits Solution: Tailored, Clinical, Human
The chemical manufacturer, with 982 plan members, was looking at a daunting annualized pharmacy spend of $1.14 million. That broke down to $94.95 per-member-per-month (PMPM).
Upon closer inspection of their utilization data, a startling trend emerged. A single specialty medication, Cabometyx, was responsible for a staggering 39% of the total plan cost. Cabometyx is a critical medication used for treating kidney and liver cancers. While the clinical necessity of the drug was clear, the financial impact was unsustainable. The plan was paying approximately $64,000 per month (pre-rebate) for this prescription.
The Solution: Clinical Expertise Meets Dose Optimization
The root cause wasn’t just the high price of the drug itself – it was how the drug was being dispensed. This issue stems from a manufacturer strategy known as parity pricing, a tactic where different strengths of the same medication have the same cost per unit. For example, a 10mg tablet and a 20mg tablet from the same manufacturer might be priced identically.
In this member’s case, the prescribed regimen of three 20mg tablets per day of Cabometyx was triple the cost compared to a once-daily 60mg tablet which could deliver the same therapeutic dose for a fraction of the price. Standard pharmacy benefits managers (PBMs) might auto-approve such claims, assuming the doctor’s prescription is the only path forward. However, this approach misses crucial opportunities for optimization.
RxBenefits’ clinical pharmacists conducted an independent peer review of the claim. They recognized that a more efficient alternative existed. A single 60mg tablet was available and clinically equivalent to taking three 20mg tablets. The pharmacists contacted the prescriber to discuss the findings, and they agreed to this safe, clinically appropriate switch.
The Impact: Better Care and Massive Saving
The results of this single intervention were immediate and dramatic. By optimizing the dosage, the plan didn’t just save a few dollars. They slashed the cost of the therapy by 67%. Here is the breakdown of the financial impact:
- Initial regimen cost: $64,000 per month, pre-rebate ($786,000 annually)
- Optimized regimen cost: $21,000 per month, pre-rebate ($252,000 annually)
- Total annual savings: $516,000
This adjustment reduced the client’s overall PMPM costs by $44.22. Beyond the cost benefits, the member benefited from a simplified daily routing – taking one pill instead of three – while receiving the same therapeutic benefit.
Actionable Insights for Your Plan
This success story illustrates a vital lesson for self-funded employers: high pharmacy costs are not always inevitable. They are often the result of inefficiencies that standard automated systems overlook.
- Watch for parity pricing impact: Drug manufacturers often price different strengths of the same medication similarly – or, conversely, price lower strengths in a way that makes multiple pills far more expensive than a single, higher-strength pill. Without human eyes reviewing these claims, plans often overpay for the exact same clinical outcome.
- Prioritize independent clinical review: PBMs often have conflicting incentives when it comes to specialty drug approvals. An independent partner who sits on your side of the table can dig deeper into claims data to find savings that others miss. In this case, it wasn’t about denying care. It was about refining it.
- Focus on “waste,” not just “price”: The chemical manufacturer didn’t need to change their plan design or shift costs to their employees to save half a million dollars. They simply eliminated waste. The $516k savings came from correcting an inefficient dispensing logic, proving that you can uphold rigorous clinical standards while still protecting the bottom line.
Is your plan overpaying for specialty medications due to inefficient dosing? It might be time to look closer at your claims data.
Visit the RxBenefits blog each month to read more success stories!
Learn more:
